William V. Tamborlane

William V. Tamborlane

Auto-generated profile, based on publicly available information

William V. Tamborlane

Department of Pediatric Endocrinology, Yale University, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
WTWilliam V. Tamborlane
William V. Tamborlane
MBMargarita Barrientos-Pérez
Margarita Barrientos-Pérez
UFUdi Fainberg
Udi Fainberg
HFHelle Frimer-Larsen
Helle Frimer-Larsen
MHMona Hafez
Mona Hafez
TBTimothy Barrett
Timothy Barrett
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. Patients who were 10 to less than 17 years of age were randomly assigned, in a 1:1 ratio, to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo for a 26-week double-blind period, followed by a 26-week open-label extension period. Inclusion criteria were a body-mass index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the patients were being treated with diet and exercise alone or between 6.5 and 11.0% if they were being treated with metformin (with or without insulin). All the patients received metformin during the trial. The primary end point was the change from baseline in the glycated hemoglobin level after 26 weeks. Secondary end points included the change in fasting plasma glucose level. Safety was assessed throughout the course of the trial. Of 135 patients who underwent randomization, 134 received at least one dose of liraglutide (66 patients) or placebo (68 patients). Demographic characteristics were similar in the two groups (mean age, 14.6 years). At the 26-week analysis of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with placebo, for an estimated treatment difference of −1.06 percentage points (P<0.001); the difference increased to −1.30 percentage points by 52 weeks. The fasting plasma glucose level had decreased at both time points in the liraglutide group but had increased in the placebo group. The number of patients who reported adverse events was similar in the two groups (56 [84.8%] with liraglutide and 55 [80.9%] with placebo), but the overall rates of adverse events and gastrointestinal adverse events were higher with liraglutide. In children and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficacious in improving glycemic control over 52 weeks. This efficacy came at the cost of an increased frequency of gastrointestinal adverse events. (Funded by Novo Nordisk; Ellipse ClinicalTrials.gov number, NCT01541215.)

26 July 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
WTWilliam V. Tamborlane
William V. Tamborlane
RBRaafat Bishai
Raafat Bishai
DGDavid Geller
David Geller
NSNaim Shehadeh
Naim Shehadeh
DADalia Al-Abdulrazzaq
Dalia Al-Abdulrazzaq
CSC. David Sjöström
C. David Sjöström
OBJECTIVE: Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately one-half of the youth fail metformin monotherapy within 1 year, insulin therapy is associated with challenges, and liraglutide requires daily injections. Consequently, the efficacy and safety of once-weekly injections of exenatide for the treatment of youth with type 2 diabetes was evaluated. RESEARCH DESIGN AND METHODS: Participants (aged 10 to <18 years) were randomized (5:2) to once-weekly exenatide 2 mg or placebo, respectively. The primary efficacy end point was change in glycated hemoglobin from baseline to week 24. Secondary efficacy end points were also evaluated, and the frequency of adverse events (AEs) was assessed. RESULTS: A total of 83 participants were randomized (exenatide, 59; placebo, 24) and 72 completed 24-week treatment (exenatide, 49; placebo, 23). At 24 weeks, the least squares mean change in glycated hemoglobin was −0.36% for the exenatide and +0.49% for the placebo groups (between-group difference, −0.85%; 95% CI −1.51, −0.19; P = 0.012). Nonsignificant least squares mean differences from baseline to 24 weeks favoring exenatide were observed: fasting glucose −21.6 mg/dL (−49.0, 5.7; P = 0.119), systolic blood pressure −2.8 mmHg (−8.0, 2.4; P = 0.284), and body weight −1.22 kg (−3.59, 1.15; P = 0.307). AEs occurred in 36 (61.0%) and 17 (73.9%) participants in the exenatide and placebo groups, respectively. CONCLUSIONS: In youth with type 2 diabetes suboptimally controlled with current treatments, once-weekly exenatide reduced glycated hemoglobin at 24 weeks and was well tolerated.

16 December 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
PCPersis V. Commissariat
Persis V. Commissariat
KHKara R. Harrington
Kara R. Harrington
AWAmanda L. Whitehouse
Amanda L. Whitehouse
KMKellee M. Miller
Kellee M. Miller
MHMarisa Hilliard
Marisa Hilliard
LLLori M. Laffel
Lori M. Laffel

1 April 2022 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
WTWilliam V Tamborlane
William V Tamborlane
LLLori M Laffel
Lori M Laffel
NSNaim Shehadeh
Naim Shehadeh
EIElvira Isganaitis
Elvira Isganaitis
MNMichelle Van Name
Michelle Van Name
ENEnsio Norjavaara
Ensio Norjavaara

12 February 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
WTWilliam V. Tamborlane
William V. Tamborlane
MHMorey W. Haymond
Morey W. Haymond
DDDavid Dunger
David Dunger
RSRavi Shankar
Ravi Shankar
RGRose Gubitosi-Klug
Rose Gubitosi-Klug
FGfor the NICHD Diabetes Working Group
for the NICHD Diabetes Working Group
The Best Pharmaceuticals for Children Act of 2002 mandated that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) carr

15 May 2013 in Diabetes Care
Verified
Journal Article
Open access
WTWilliam V. Tamborlane
William V. Tamborlane
GKGeorgeanna Klingensmith
Georgeanna Klingensmith